Anti-inflammatory agent 52 (compound 7j) is an orally active, selective COX-2 inhibitor with the capability to induce G2/M phase arrest and exhibit anti-HT29 transfer activity. It demonstrates moderate anti-inflammatory efficacy and a notable safety profile. Additionally, this compound possesses the uncommon ability to inhibit tumor growth in mouse models, indicative of its anticancer properties [1].

抗炎药物52（化合物7j）（0.25 μM；24小时）在 HT29 细胞中有效抑制集落形成，并导致细胞周期在 G2/M 阶段停滞[1]。

抗炎药物52（化合物7j）（50 mg/kg；口服；隔日给药，连续两周）能有效降低艾利希实体瘤小鼠模型中的肿瘤体积和重量[1]。